ShareValue scores for NVNO: Valuation 64, Quality 55, Growth 49, Health 52.

enVVeno Medical Corp logo

NVNO
NASDAQ

enVVeno Medical Corp

$10.15(-8.31%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 17%
Valuation
64
Fair Value
Price vs Value
Quality
55
Moderate
Business Strength
Growth
49
Moderate
Revenue & Earnings
Health
52
Moderate
Financial Stability
Momentum
52
Neutral
Price Trend

Company Details

About

enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026